Angel City's Savy King has heart surgery following on-field collapseNew Foto - Angel City's Savy King has heart surgery following on-field collapse

Angel City defender Savy King was recovering from heart surgery following her collapse on the field during a National Women's Soccer League match on Friday night. King was taken to Cedars-Sinai Medical Center in Los Angeles following themedical event in the second half of Angel City's match against the Utah Royals.Doctors who evaluated King discovered a heart abnormality, and she underwent surgery Tuesday. "She is now resting and recovering surrounded by her family, and her prognosis is excellent," the team said in a statement. King's family released a joint statement thanking the team's medical staff, King's fellow players and the hospital medical staff for her care. "On behalf of our entire family, along with Savy, we have been so moved by the love and support from Angel City players, staff, fans and community, as well as soccer fans across the country," the statement said. "We are blessed to share Savy is recovering well and we are looking forward to having her home with us soon." Players on both sides were visibly shaken as trainers rushed to King's side aftershe went down in the 74th minute of Friday's match.She was attended to for some 10 minutes before she was stretchered off the field on a cart. Angel City said King was transported to the hospital but was responsive and undergoing further evaluation. "We are grateful to the Angel City medical staff as well as to local paramedics who handled this difficult situation seamlessly," the NWSL said in a statement on Saturday. In an Instagram story, Washington Spirit national team forward Trinity Rodman offered prayers for King and her family, adding: "In no world should that game have continued." The league said in its statement that it would review its policies to determine if changes needed to be made. NWSL rules for 2025 state that the league "recognizes that emergencies may arise which make the start or progression of a Game inadvisable or dangerous for participants and spectators. Certain event categories automatically trigger the League Office into an evaluation of whether delay or postponement is necessary." There were 12 minutes of stoppage time added to the match. Angel City won the game 2-0. King, 20, was the second overall pick in the 2024 NWSL draft by expansion Bay FC and played 18 games for the club. She was traded to Angel City in February and had started in all eight games for the team this season. ___ AP soccer:https://apnews.com/hub/soccer

Angel City's Savy King has heart surgery following on-field collapse

Angel City's Savy King has heart surgery following on-field collapse Angel City defender Savy King was recovering from heart surgery fol...
Formula 1: How to watch the Emilia-Romagna Grand Prix on TV and what to knowNew Foto - Formula 1: How to watch the Emilia-Romagna Grand Prix on TV and what to know

IMOLA, Italy (AP) — Here's a guide that tells you what you need to know about Sunday's Emilia-Romagna Grand Prix. It's the seventh round of the 2025Formula 1season. How to watch the Emilia-Romagna Grand Prix on TV — In the U.S., on ESPN. —Other countries are listed here. What is the Emilia-Romagna GP schedule? — Friday: First and second practice sessions. — Saturday: Third practice and qualifying. — Sunday: Emilia-Romagna Grand Prix, 63 laps on the 4.91-kilometer (3.05-mile) Imola circuit. Starts at 9 a.m. ET (1300 GMT). Where is the Emilia-Romagna Grand Prix taking place? The Imola circuit — officially the Autodromo Internazionale Enzo e Dino Ferrari — is a narrow, old-school circuit which is a favorite with many drivers. It's a venue with a history of tragedy after three-time F1 champion Ayrton Senna and Austrian driver Roland Ratzenberger were both killed during the 1994 race weekend. Italy is the only country other than the United States with more than one race on the 2025 F1 calendar. The Italian Grand Prix name belongs to Monza, which hosts in September, so this week's race is named after the Emilia-Romagna region. Imola is in the last year of its contract. What happened in the last race? Oscar Piastri extended his standings lead with his third win in a row, taking victory at the Miami Grand Prix. That came after his teammate and title rival Lando Norris went head-to-head with defending champion Max Verstappen and ran off track. Norris had taken valuable points a day earlier by winning the sprint race. What do I need to know about F1 so far? Get caught up: —Oscar Piastri wins at Miami for 3rd straight F1 victory, 4th win of season for championship leader —Franco Colapinto is back in F1 with Alpine after the team dropped Jack Doohan —Alpine team principal Oliver Oakes' resignation came days after police charged brother —Ferrari frustration mounts as Lewis Hamilton and Charles Leclerc struggle at Miami Grand Prix —Cadillac F1 makes its entrance as official team at Miami Grand Prix as questions swirl about lineup Key stats at Imola 6 — The win in Miami was the sixth of Piastri's career, taking him past teammate Norris' five career victories. It's Piastri's third season in F1, and Norris is in his seventh year. 4 — Piastri can become the first Australian to win four F1 races in a row since Jack Brabham in 1966. 2 — Franco Colapinto has been a mid-season replacement twice now in F1, first with Williams last year and now with Alpine, replacing Pierre Gasly. Just like in 2024, his first race of the year is in Italy. What they're saying "I've got good momentum behind me and I'm extremely focused heading into this first race of the European swing of the season." — Oscar Piastri. "I am very excited to be going into race week for the first time since December. I am very grateful for this opportunity and now I have to get up to speed and showcase what I am capable of doing in the car." — Franco Colapinto. ___ AP auto racing:https://apnews.com/hub/auto-racing

Formula 1: How to watch the Emilia-Romagna Grand Prix on TV and what to know

Formula 1: How to watch the Emilia-Romagna Grand Prix on TV and what to know IMOLA, Italy (AP) — Here's a guide that tells you what you ...
An NBA star was named 'most overrated' by his peers. He's having the last laughNew Foto - An NBA star was named 'most overrated' by his peers. He's having the last laugh

Tyrese Haliburton arrived for a photoshoot in a Las Vegas casino last summer holding onto a pair of silver-tipped cowboy boots and a grudge. Before the Indiana Pacers guard slipped into a denim outfit and in front of a magazine's camera, he rattled off all he was grateful for: consecutive appearances at the league's All-Star game, a contract that would pay him an average of about $52 million annually, and an invitation to play for the United States in the Paris Olympics. Yet what Haliburton seemedespeciallythankful for was something else entirely — a perceived criticism that "everybody thinks my success in the first half of last season was a fluke," he said. For a player who had gone from effectively being cut from his teenaged travel squad to an NBA All-Star in less than a decade while fueled by collecting slights, it might as well have been like being handed a gift. "I'm at my best," Haliburtontold me then, "when people are talking s--- about me." One year later, the NBA is learning that still holds true. Since being named the NBA's "most overrated" player in April by an anonymous vote of his peers,as polled by The Athletic, Haliburton has authored a revenge tour that has landed Indiana in the Eastern Conference Finals for a second consecutive season. The Pacers are now four wins away from their first appearance in the NBA Finals in 25 years. As Haliburton was making all five 3-pointers he attempted in the second quarter of Tuesday's Game 5 against Cleveland — en route to 31 points in the series-clinching victory that knocked out the Eastern Conference's top seed — none less than LeBron James referenced, and refuted, the overrated label. Haliburton has appeared to relish getting the last laugh. After hearing chants of "overrated" in Milwaukee during a first-round series Haliburton, who grew up in Oshkosh, Wisconsin, won the series by driving past Giannis Antetokounmpo, one of the NBA's toughest defenders, for a basket with a second remaining in overtime. He celebrated with a post on X for emphasis. Of the 90 players who voted for most overrated in The Athletic's poll, 14.4 percent chose Haliburton, or about 13 players overall in a league of 450. It could have followed Haliburton's markedly slow start to the season as he struggled to play through injury. Still, the poll followed expletive-laden criticismon a podcastfrom Hall of Fame point guard Tim Hardaway Sr., who said Haliburton "thinks he's all that." The sentiments from players both active and retired, though pointed, were hardly universal. But they were all Haliburton needed, said Bryan Johnikin, who coached Haliburton as a teenager on a Milwaukee-based AAU team and remains close to the guard. He has watched Haliburton's heroics help Indiana beat Milwaukee, then take down Cleveland, with little surprise. "I'm not, personally, because as soon as I know they called him overrated or said he don't belong, it really motivates him," Johnikin said. Johnikin met the guard when Haliburton was 14 years old and wounded after learning his former AAU team wasn't keen on him to return. It was Johnikin's role as Haliburton's new coach, he said, to understand what motivated the point guard. Being passed over for Wisconsin's "Mr. Basketball" honor, awarded to the state's top high schooler, did the trick. So did arriving for college at Iowa State as a relatively low-level recruit and leaving it as a much-debated draft prospect in part because of the low release of his jump shot. What those evaluations perhaps missed was Haliburton's ability to think his way through a problem, Johnikin said. Knowing pace of play typically drops from the regular season to the playoffs, Indiana has done the opposite, running at the postseason's third-fastest pace. "I guarantee you, if you put everybody that's in the playoffs, put them in the classroom, he's gonna be the smartest guy," Johnikin said. Haliburton has averaged 17.5 points, 9.3 assists and 5.5 rebounds in the playoffs, where the Pacers are 17 points better per 100 possessions with Haliburton on the court versus when he sits; no Indiana teammate has a higher on/off rating. "Hali, that boy he making a lot of people look crazy with that 'overrated' s---," former NBA player Dorell Wrightsaid on a podcast with Dwyane Wade this week. "We need a recount." "His game don't look like you expect it to, right?" Wade said. "He's got an unorthodox form ... he ain't going to be top 10 in the league in scoring, but he's still going to dominate the game." Among NBA superstars Haliburton, who runs a YouTube channel in which he plays video games against his brother and prefers mid-sized Indianapolis to the league's shinier, big-city markets, has a notably placid personality. Yet as a devoted fan since childhood of professional wrestling and its theatrics, he is also quick to embrace the villainous role of the "heel." In addition to his breakout NBA season, and earning an Olympic gold medal in 2024, one of Haliburton's personal highlights last year was being written into a skit during WWE Smackdown, in which he and New York Knicks guard Jalen Brunson stared one another down. (In real life, the two are friends.) These playoffs have felt like a long, extended stare-down with the rest of the league. Haliburton followed his series-winning comeback against Milwaukee by stunning Cleveland with a game-winning 3-pointer to cap another improbable comeback in Game 2. Research by ESPN found that since 1998, teams were 3-1,640 when trailing by seven or more points in the final minute of the fourth quarter or overtime. In this postseason alone,Indiana accounts for two of those three wins. "I think there is always commentary behind what I do, positive or negative, and I mean it's hilarious because a lot of times it's people who know nothing about me have so much to say," Haliburton said after a second-round victory. "It's usually people who don't come around or don't spend any time around me that have the most to say, but that's all part of it. I'm a basketball player, I love what I do. "... I feel like criticism is sometimes warranted, sometimes it's not but it's all a part of it." Last year, during warmups before Game 7 of a second-round series against New York in Madison Square Garden, Haliburton noticed a specific fan he heard making critical comments and became determined to make him a one-fan motivational tool, turning to glare at the fan after every basket. The Pacers won, and it reinforced to Johnikin a strategy that could be worth every postseason penny in the Eastern Conference Finals — where they could face the Knicks or Boston Celtics — and possibly the NBA Finals. Indiana should "just pay people to sit in the front row and just talk crazy to Ty, because that's when he gets going," Johnikin said. "I'm not worried about him when he goes to New York. Spike Lee and the rest of them talking crazy, he loves that. I call it the 'it factor.' "If you talk crazy to Tyrese he's gonna go, for sure."

An NBA star was named 'most overrated' by his peers. He's having the last laugh

An NBA star was named 'most overrated' by his peers. He's having the last laugh Tyrese Haliburton arrived for a photoshoot in a ...
FDA upheaval pushes some biotech firms to plan early trials out of USNew Foto - FDA upheaval pushes some biotech firms to plan early trials out of US

By Maggie Fick LONDON (Reuters) -Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs watchdog under the Trump administration may delay regulatory reviews, executives, investors, and consultants told Reuters. The U.S. Food and Drug Administration is seen as the global gold standard for drug regulation and companies typically seek American approval first because it provides access to the world's most lucrative drug market. But mass layoffs, leadership exits and the restructuring of the FDA under President Donald Trump are prompting some smaller biotechs to rethink traditional pathways for bringing new medicines to market. Reuters spoke to seven biotech executives, investors, and consultants who said that the staff departures and policy changes at the FDA had prompted some firms to consider launching trials in other international markets - such as the European Union and Australia - and engaging with regulators in those regions earlier in the drug development process. "We know that across our companies, the discussions include whether to go ex-U.S. because of recent FDA uncertainty," said Peter Kolchinsky, managing partner at RA Capital, a major investor in early-stage biotech firms and publicly traded companies with approximately $9 billion in assets under management. The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's restructuring aims to streamline functions such as IT and communications, and reduce conflicts of interest among its staff and advisors. Consultant Matthew Weinberg of ProPharma Group said his firm is fielding more inquiries from biotech companies about preparing filings with the European Medicines Agency and setting up clinical trials - a shift he attributes to growing concerns about FDA stability. "Historically, companies went to the U.S. first. That may be changing," he said. It is unclear if biotech companies' increasing engagement with the EMA marks a real shift or a tactic to pressure the FDA, given the importance of the U.S. market, a source with knowledge of the matter told Reuters. An EMA spokesperson said it has not seen an increase in scientific advice requests or clinical trial applications, noting it would be early for any such shifts to be reflected in submissions. NEW APPROACHES A loss of confidence in the FDA could reshape drug development, reduce U.S. leadership in innovation, and increase costs for the struggling biotech sector, five of those interviewed said. "What's happening has forced all of us to discuss other approaches," said Sabrina Martucci Johnson, CEO of Dare Bioscience, a San Diego-based women's health biotech worth $25 million that received FDA approval in 2021 for its first product. "We are definitely looking at Europe first for certain products where the need is great and the U.S. regulatory path has become more uncertain or slower." Trump on Monday signed an executive order directing drugmakers to lower the prices of their medicines in line with other countries.  Commenting on the executive order, Swiss drugmaker Roche on Tuesday said it is concerned that the order "will undermine the U.S.' position as the world's leading pharmaceutical and healthcare ecosystem." Some biotech executives spoke about early-stage testing on condition of anonymity to avoid drawing attention to their companies or risking retribution for criticising the Trump administration. One biotech CEO said their company plans to seek approval from the EMA to run early-stage clinical trials of its oncology treatment in three European countries - in addition to the trial of the same treatment it launched in the U.S. last October. The expanded European strategy will cost about $1 million in additional filings, consultants, and contract research organisation support - plus several million more to run the trials. "We cannot just hope that things will turn around and that the cuts at the FDA will not have any impact on our business," the executive said. "The irony of this is it goes against the grain of 'America First', because we are offshoring away from the U.S. over to Europe." SLOWER BUT STABLE Another U.S. biotech told Reuters it opted to run two early-stage trials in Australia this month rather than in the U.S. Although some small biotechs had already started to conduct their first in-human trials outside the U.S., particularly in Australia where it is 30% to 40% cheaper, the biotech CEO said that in their firm's case, the decision was driven by FDA staffing cuts and uncertainty. A third biotech CEO said at least two members of the eight-person FDA team reviewing its early-stage trial for an mRNA rare disease therapy have left. They worry this turnover could delay FDA review of trial data. When asked about the impact of shifts at the FDA during earnings calls this month, executives from several big pharma companies including GSK, Merck & Co and Sanofi said they had so far not experienced any changes in their interactions with the regulator. Companies typically file for regulatory approval in the U.S. first to gain access to a market worth approximately $635 billion annually. Even a month or two delay in a regulatory step with the FDA could be existential, said the biotech CEO with the mRNA rare disease therapy. Executives stressed they still intend to run late-stage trials in the U.S. to launch products there. "Europe has been perceived as a little slower, but it has benefited -- and is benefiting now -- from being stable," said Owen Smith, a partner at 4BIO Capital, a London-based venture capital firm that invests in early-stage biotech companies. (Reporting by Maggie Fick; Additional reporting by Emilio Parodi in Milan; Editing by Josephine Mason and Suzanne Goldenberg)

FDA upheaval pushes some biotech firms to plan early trials out of US

FDA upheaval pushes some biotech firms to plan early trials out of US By Maggie Fick LONDON (Reuters) -Some U.S. biotech companies are consi...
Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu saysNew Foto - Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says

ISTANBUL (Reuters) - Turkish President Tayyip Erdogan met online with U.S. President Donald Trump, Saudi Crown Prince Mohammed bin Salman and Syrian President Ahmed al-Sharaa, state-owned Anadolu news agency reported on Wednesday. Erdogan said during the meeting that Trump's decision to lift sanctions on Syria is of historic importance, Anadolu reported. Trump made the surprise announcement on Tuesday that the U.S. would lift all sanctions on the Islamist-led government in Syria, which had been a key goal for Turkey. (Reporting by Ezgi Erkoyun; Editing by Jonathan Spicer)

Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says

Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says ISTANBUL (Reuters) - Turkish President Tayyip Erdogan met...

 

VS JORNAL © 2015 | Distributed By My Blogger Themes | Designed By Templateism.com